Cyteir Therapeutics Alpha and Beta Analysis
| CYTDelisted Stock | USD 2.76 0.01 0.36% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Cyteir Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Cyteir Therapeutics over a specified time horizon. Remember, high Cyteir Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Cyteir Therapeutics' market risk premium analysis include:
Beta 0.47 | Alpha 0.52 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Cyteir |
Cyteir Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Cyteir Therapeutics market risk premium is the additional return an investor will receive from holding Cyteir Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Cyteir Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Cyteir Therapeutics' performance over market.| α | 0.52 | β | 0.47 |
Cyteir Therapeutics Fundamentals Vs Peers
Comparing Cyteir Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Cyteir Therapeutics' direct or indirect competition across all of the common fundamentals between Cyteir Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Cyteir Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Cyteir Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Cyteir Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Cyteir Therapeutics to competition |
| Fundamentals | Cyteir Therapeutics | Peer Average |
| Return On Equity | -0.24 | -0.31 |
| Return On Asset | -0.14 | -0.14 |
| Current Valuation | (20.89 M) | 16.62 B |
| Shares Outstanding | 36 M | 571.82 M |
| Shares Owned By Insiders | 6.63 % | 10.09 % |
| Shares Owned By Institutions | 76.83 % | 39.21 % |
| Number Of Shares Shorted | 319.73 K | 4.71 M |
Cyteir Therapeutics Opportunities
Cyteir Therapeutics Return and Market Media
The Stock received some media coverage during the period. Price Growth (%) |
| Timeline |
1 | Catalyst to Report Q1 Earnings Whats in the Cards - Zacks Investment Research | 05/02/2023 |
2 | Cyteir Therapeutics Shares Jump percent After Plans to Dissolve Company | 06/30/2023 |
About Cyteir Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Cyteir or other delisted stocks. Alpha measures the amount that position in Cyteir Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Cyteir Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Cyteir Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cyteir Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Cyteir Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Cyteir Therapeutics. Please utilize our Beneish M Score to check the likelihood of Cyteir Therapeutics' management manipulating its earnings.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Cyteir Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Consideration for investing in Cyteir Stock
If you are still planning to invest in Cyteir Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cyteir Therapeutics' history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |